SNU-449

SNU-449 is a human hepatocellular carcinoma (HCC) cell line widely used in research to study liver cancer biology, drug resistance, apoptosis, and novel therapeutic strategies. As hepatocellular carcinoma is one of the most aggressive and common liver malignancies with poor prognosis, cell lines like SNU-449 are critical for understanding the molecular mechanisms underlying cancer progression and drug responses. SNU-449 has been particularly useful in studies involving apoptosis and ferroptosis, a regulated form of cell death associated with iron-dependent lipid peroxidation. For example, research has shown that agents like sorafenib, a standard treatment for advanced HCC, and artesunate synergize to induce ferroptosis in SNU-449 cells. This combination exacerbates lipid peroxidation and oxidative stress, leading to extensive cancer cell death. This synergy occurs because artesunate promotes lysosomal ferritin degradation (ferritinophagy), which increases free iron availability, while sorafenib impairs mitochondrial function and depletes glutathione, a critical antioxidant. SNU-449 has also been used to explore apoptotic pathways in liver cancer. For example, genistein, a natural isoflavone, induces apoptosis in SNU-449 cells by down-regulating thioredoxin-1 (Trx1), an antioxidant protein that regulates reactive oxygen species (ROS) and inhibits apoptosis. Genistein treatment increases ROS levels and activates apoptosis-related pathways, including caspase-3 activation and DNA fragmentation. These findings highlight SNU-449 as a valuable model for studying both apoptosis and ferroptosis, aiding in the development of targeted therapies for hepatocellular carcinoma. Liver cancer cell lines, Liver, Adult hepatocellular carcinoma, Growth Conditions: Adherent, Biosafety level: BSL 1